BioCentury
ARTICLE | Company News

Alligator Bioscience, J&J deal

August 17, 2015 7:00 AM UTC

Alligator granted Johnson & Johnson’s Janssen Biotech Inc. unit exclusive, worldwide rights to develop and commercialize ADC-1013. Alligator expects to complete a Phase I trial of the antibody-based CD40 receptor activator immunotherapy in solid tumors in October 2017.

Janssen will be responsible for development and commercialization of ADC-1013 following completion of the trial and plans initially to target hematologic cancers and solid tumors. Alligator will receive an undisclosed upfront payment and is eligible for undisclosed development, regulatory and commercial milestones, plus undisclosed tiered royalties. ...